Dr. Martens (LON:DOCS) Stock Price Down 2.8% – Time to Sell?

Dr. Martens plc (LON:DOCS)’s share price fell 2.8% during mid-day trading on Thursday . The company traded as low as GBX 70.40 and last traded at GBX 71.08. 1,442,787 shares were traded during mid-day trading, a decline of 80% from the average daily volume of 7,223,208 shares. The stock had previously closed at GBX 73.10.

Analyst Ratings Changes

A number of equities analysts recently weighed in on DOCS shares. Berenberg Bank lowered their price objective on shares of Dr. Martens from GBX 114 to GBX 110 and set a “buy” rating for the company in a research report on Tuesday, May 19th. Royal Bank Of Canada reissued a “sector perform” rating and issued a GBX 100 target price on shares of Dr. Martens in a research report on Tuesday, June 2nd. Two research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, Dr. Martens has an average rating of “Moderate Buy” and an average target price of GBX 105.

Dr. Martens Stock Performance

The company has a debt-to-equity ratio of 108.85, a quick ratio of 1.13 and a current ratio of 2.61. The company has a market capitalization of £689.12 million, a price-to-earnings ratio of 30.00, a P/E/G ratio of 6.40 and a beta of 0.26. The firm has a 50-day simple moving average of GBX 77.36 and a two-hundred day simple moving average of GBX 70.57.

Insider Buying and Selling

In other Dr. Martens news, insider Giles Wilson bought 68,313 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The shares were purchased at an average cost of GBX 72 per share, with a total value of £49,185.36. Also, insider Ije Nwokori bought 118,516 shares of Dr. Martens stock in a transaction on Thursday, June 25th. The shares were acquired at an average price of GBX 72 per share, for a total transaction of £85,331.52. Insiders purchased 300,091 shares of company stock valued at $22,061,656 in the last 90 days. Company insiders own 2.94% of the company’s stock.

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.